Subscribe to Newsletter
Outside the Lab Microbiology and immunology, Clinical care

The Castleman Criteria

When your symptoms belong to a rare illness, such as Castleman disease (a lymph node disorder), the diagnostic outlook is bleak. Idiopathic multicentric Castleman disease (iMCD) is a life-threatening subtype that affects multiple lymph nodes. With no established diagnostic protocol in place, sufferers may remain undiagnosed – or misdiagnosed with lymphoma or autoimmune disorders – for years. To offer a solution, a multinational team of investigators banded together to pioneer a set of identification criteria (1).

Major Criteria

Histopathological features consistent with iMCD on excisional lymph node biopsy
Enlarged (≥1 cm) lymph nodes in two or more lymph node stations

Minor Criteria

Clinical Laboratory
Constitutional symptoms Elevated C-reactive protein
Hepatosplenomegaly Anemia
Edema or effusions Hypoalbuminemia
Eruptive cherry hemangiomatosis or violaceous papules Thrombocytopenia or thrombocytosis
  Renal dysfunction
Lymphocytic interstitial pneumonitis Polyclonal hypergammaglobulinemia

Table 1. Major and minor criteria for the diagnosis of iMCD.

The journey began with a review of 244 clinical cases and 88 lymph node biopsies from iMCD patients. Fifteen months of investigation yielded a set of major and minor criteria for diagnosis (see Table 1). To confirm iMCD, patients must exhibit at least two major and two minor criteria, including at least one abnormal laboratory result.

Next, the investigators used their criteria to retrospectively diagnose patients from a clinical trial of siltuximab, a therapeutic tested on iMCD patients. Trial participants who did not meet the criteria had no response to the drug, while those who did had a 43 percent response rate.

The outcome seems to show the effectiveness of the criteria, but that doesn’t mean the job is done. Using ACCELERATE, a research platform that collates iMCD clinical data, the researchers aim to keep fine-tuning their method. But even in this early stage, the investigators believe their Castleman criteria could help turn the tide in the fight against iMCD.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. DC Fajgenbaum et al., “International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease”, Blood, [Epub ahead of print] (2017). PMID: 28087540.
About the Author
William Aryitey

My fascination with science, gaming, and writing led to my studying biology at university, while simultaneously working as an online games journalist. After university, I travelled across Europe, working on a novel and developing a game, before finding my way to Texere. As Associate Editor, I’m evolving my loves of science and writing, while continuing to pursue my passion for gaming and creative writing in a personal capacity.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register